Case Studies

Case study
Unifying Citations, Cross-Checks and Human Sign-Off for Accountable AI-Assisted CSR Authoring
Case study
Unifying Citations, Cross-Checks and Human Sign-Off for Accountable AI-Assisted CSR Authoring
Case study
From Manual Cross-Referencing and Hand-Checked Numbers to Cited, Cross-Checked CSR Drafting
Case study
From Manual Cross-Referencing and Hand-Checked Numbers to Cited, Cross-Checked CSR Drafting
Case study
Launch Intelligence: Turning the Launch Forecast into a Decision Engine
Case study
Launch Intelligence: Turning the Launch Forecast into a Decision Engine
Case study
AI Pre MLR Content Intelligence
Case study
AI Pre MLR Content Intelligence

Events

16
Mar
2026

ATLAS 2026: Pharma CXO Roundtable

Navigate with Agentic AI Insights

20
Jun
2025

Pharma CXO Roundtable 2025

Advancing Life Sciences Business Process Innovation Using Autonomous Agentic Al

18
May
2025

PMSA 2025 Annual Conference

Revolutionizing Pharma Commercialization with Agilisium's AI Agents

2
Apr
2025

Bio-IT World 2025

Supercharge Life Sciences Innovation Using AI Agents

White Papers

Beyond Human-in-the-Loop: Why AI in Pharma Needs Human-Aided Intelligence (HAI)

Discover how Human-Aided Intelligence (HAI) combines AI capabilities with human expertise to improve decision-making across pharmaceutical workflows.

Six Capability Pillars of the AI-Era Life Sciences : From Six Capabilities to Evidence-Backed Deployment Readiness

Life sciences organizations are building AI capabilities, but determining who is ready for real client engagements remains a challenge. Course completion and skills assessments alone cannot establish whether professionals can combine domain expertise, AI judgment, and business acumen to solve complex problems. Without evidence of demonstrated capability, deployment decisions remain difficult to validate.

From Reactive to Predictive: How Clinical Quality Intelligence Can Redefine Inspection Readiness in Clinical Trials

Clinical trial quality management still runs on reactive workflows - TMF gaps surface close to inspection, EDC anomalies get escalated late, and protocol deviations pile up without trial-level trending. With ICH E6(R3) now in force as the global GCP standard, that model is no longer defensible.